Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085196 | 0.79 | MAPT (0.60) | MAPTGAAHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL679125 | 0.77 | TSHR (0.69) | MAPTGAAHPGDSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7130171 | 0.76 | TSHR (0.67) | MAPTGAAHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4110940 | 0.74 | MAPT (0.86) | MAPTGAAHPGDRAB9ASMN1; SMN2 | |
| Ethyl Phenylcarbamate SCHEMBL11593824 | 0.74 | RAB9A (0.75) | MAPTGAAHPGDRAB9ASMN1; SMN2 | |
| Ethyl Phenylcarbamate SCHEMBL264865 | 0.74 | RAB9A (0.75) | MAPTGAAHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL22648544 | 0.74 | MAPT (0.59) | MAPTGAAHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL5592685 | 0.74 | MAPT (0.63) | MAPTGAAHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL14791253 | 0.74 | MAPT (0.49) | MAPTGAAHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL9305595 | 0.74 | HSD11B1 (0.56) | MAPTGAAHPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | MAPT 2813/4885GAA 272/4885HPGD 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.